Trevi Therapeutics (NASDAQ:TRVI) Now Covered by Analysts at HC Wainwright

HC Wainwright began coverage on shares of Trevi Therapeutics (NASDAQ:TRVI) in a research note issued to investors on Friday, MarketBeat.com reports. The brokerage issued a buy rating and a $6.00 price objective on the stock.

A number of other equities research analysts have also recently commented on TRVI. Raymond James initiated coverage on Trevi Therapeutics in a research note on Friday. They set an outperform rating and a $9.00 price objective for the company. EF Hutton Acquisition Co. I raised Trevi Therapeutics to a strong-buy rating in a research note on Monday, August 19th. Needham & Company LLC reissued a buy rating and set a $8.00 price objective on shares of Trevi Therapeutics in a research note on Wednesday, May 8th. Finally, Rodman & Renshaw began coverage on shares of Trevi Therapeutics in a report on Thursday, June 13th. They set a buy rating and a $7.00 price objective for the company. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Trevi Therapeutics presently has a consensus rating of Buy and a consensus target price of $7.80.

Trevi Therapeutics Price Performance

TRVI stock opened at $3.16 on Friday. The business has a fifty day moving average price of $2.84 and a 200 day moving average price of $2.84. Trevi Therapeutics has a fifty-two week low of $0.97 and a fifty-two week high of $4.00. The stock has a market capitalization of $229.38 million, a price-to-earnings ratio of -9.29 and a beta of 1.00.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.01). During the same quarter last year, the business posted ($0.07) EPS. On average, equities analysts expect that Trevi Therapeutics will post -0.46 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Thomas Sciascia sold 18,660 shares of the firm’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $2.76, for a total transaction of $51,501.60. Following the sale, the insider now directly owns 220,315 shares in the company, valued at $608,069.40. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last three months, insiders have sold 23,315 shares of company stock worth $65,123. Company insiders own 24.37% of the company’s stock.

Institutional Trading of Trevi Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. American Century Companies Inc. lifted its position in Trevi Therapeutics by 17.1% during the 2nd quarter. American Century Companies Inc. now owns 54,108 shares of the company’s stock worth $161,000 after buying an additional 7,902 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in Trevi Therapeutics by 87.6% during the second quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company’s stock worth $73,000 after acquiring an additional 11,450 shares in the last quarter. Price T Rowe Associates Inc. MD acquired a new position in Trevi Therapeutics during the first quarter valued at approximately $47,000. Hsbc Holdings PLC bought a new position in Trevi Therapeutics in the second quarter valued at approximately $61,000. Finally, Rhumbline Advisers increased its position in shares of Trevi Therapeutics by 44.8% during the 2nd quarter. Rhumbline Advisers now owns 75,218 shares of the company’s stock worth $224,000 after purchasing an additional 23,263 shares during the last quarter. 95.76% of the stock is currently owned by institutional investors and hedge funds.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.